TABLE 2.
Summary of reported baseline frequency of clinically relevant NS3 amino acid changes in patients chronically infected with HCV genotype 1a and naive to HCV protease inhibitorsf
| Study characteristics | Reported amino acid substitution(s) (%)a at NS3 amino acid position: |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| V36 | F43 | T54 | V55 | Q80 | S122 | I132 | R155 | A156 | V158 | D168 | I170 | L175 | |
| EU HCV and Los Alamos 2008 (25), n = 131 | M (<1) | − | S (<1) | NA | K (34), R (<1) | NA | NA | K (<1) | − | NA | E (<1) | − | NA |
| Gilead Science and Los Alamos 2010 (12),b n = 268 | NA | NA | NA | NA | K (47) | NA | NA | NA | NA | NA | NA | NA | NA |
| Los Alamos 2013 (18), n = 680 | L (<1), M (<1) | S (<1) | S (1) | NA | K (37), R (<1) | NA | NA | G (<1), K (<1) | − | NA | E (<1), G (<1) | − | NA |
| GenBank analysis 2012 (15), n = 621 | L (<1) | − | − | A (2) | K (42) | NA | NA | − | − | NA | E (<1) | − | − |
| French cohort (26), n = 46 | NA | NA | NA | NA | K (7) | G (9) | V (2) | NA | NA | NA | NA | NA | NA |
| Italian cohorts (13, 14),c n = 98 | L (6) | − | S (4) | A/I (3) | K (14) | NA | NA | − | − | − | − | − | − |
| Swedish cohort (17), n = 53 | L (4) | NA | A (2), S (8) | A (8), I (6) | K (6), R (4) | − | NA | NA | NA | NA | − | NA | NA |
| Brazilian cohort (19),d n = 37 | − | − | A (3), S (3) | A (3) | K (3), R (3) | G (5) | − | K (3) | T (5) | − | G (3) | − | − |
| Scottish cohort (20),e n = 38 | M (5) | − | S (3) | A (3) | K (16) | NA | NA | − | − | NA | A (3) | − | NA |
| Telaprevir clinical studies (16), n = 2,111 | I/M (<1), L (2) | − | A (<1), S (3) | A (3), I (2) | K (38), R (<1) | NA | V (<1) | K (<1) | − | − | E (<1) | T (<1) | − |
| Faldaprevir clinical studies (present analysis), n = 437 | L (1), M (<1) | − | S (2) | A (3), I (<1) | K (23), R (<1) | G (10) | V (<1) | K (<1) | − | − | E (<1) | T (<1) | − |
In populations of protease inhibitor-naive patients infected with HCV genotype 1a. Population-based sequencing for NS3 sites with no variant listed, the wild-type amino acid, or amino acids not associated with PI resistance were reported (−) or data were not available (NA).
Only positions 54 and 80 were reported.
Two studies carried out in Italy and reporting similar results were pooled. Included 55 HIV/HCV-coinfected patients.
Genotype not confirmed. Based on the prevalent genotype in the region of study.
HIV/HCV-coinfected patients.
In the present analysis and in previously published studies.